Spherix Announces Positive Phase 2 Study Results
... separate 3-hour oral glucose and tagatose tolerance
tests. The subjects were also given 75 g of ... a novel hexose: Acute effects on carbohydrate tolerance
in subjects with and without type 2 diabetes. ... participated in 11 separate 2-h meal or glucose tolerance
tests. A total of 33 non-diabetic, healthy ...
Overweight Siblings of Children With Type 2 Diabetes Likely to Have Abnormal Blood Sugar Levels
... looked at the risk of abnormal glucose tolerance
among siblings of children diagnosed with type 2 ... having abnormal glucose levels (impaired glucose tolerance
or type 2 diabetes) than other overweight ... screening of obese children for abnormal glucose tolerance
by primary care providers. This could also help ...
Genaera Corporation Presents Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at Keystone Symposia
leads to marked improvement in glucose tolerance
and lowers plasma insulin
levels in diet-induced ... and improves fasting blood glucose
and glucose tolerance
in hyperglycemic animal models, and that ... in glucose tolerance,
as measured by oral glucose tolerance
testing can be sustained during long
periods of ...
Genaera Corporation Presents Additional Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at American Diabetes Association
... poster presentation, entitled "Trodusquemine (MSI-1436) Improves
and HbA1C Levels in Murine Models of Insulin Resistance"
concluded that ... dose of MSI-1436 demonstrated
a significant improvement in oral glucose tolerance
(OGTT) within 24 hours
of dosing, and prior to any significant change in ...
Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
... pharmacodynamic impacts of the drug (improvement of abnormal glucose tolerance
and appetite suppression) and to fully validate its proof-of-concept ... reduces body fat (with no reduction of lean mass), and
improves glucose tolerance
via inhibition of a unique combination of
signaling pathways in a mouse ...
Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
... the first opportunity to study
short-term glucose control indices, glucose tolerance
sensitivity. The poster presented at NAASO, "First in Human ... reduces body fat (with no reduction of lean mass), and
improves glucose tolerance
via inhibition of a unique combination of
signaling pathways in a mouse ...
Emphasys Medical Announces Positive Data From Pivotal Trial for Patients With Emphysema
... Zephyr(R) Endobronchial Valve (EBV) improved lung function and
in patients with emphysema. These data were presented at
the CHEST 2007 ... by forced
expiratory volume in one second (change in FEV1) and exercise tolerance
measured by a six minute walk test (6MWT) both at six months. The ...
September is National Pain Awareness Month
... you from being exposed to narcotics and
you don't develop an addiction or tolerance
to it." Additionally, there are no withdrawal symptoms and patients ... all available
treatments, as providers and patients may be concerned about tolerance
addiction problems related to opioid treatments. About PRIALT ...
Schering-Plough Expands Vicriviroc Phase II Study in Treatment-Naive Patients With HIV
... transcriptase inhibitor (NNRTI) or a ritonavir-boosted PI.(4) While these combinations have been demonstrated to be highly effective, long-term tolerance
may be limited by the toxicity specifically associated with nucleosides, which can include neuropathy, myopathy, renal toxicity, hepatic steatosis, ...
King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use
... was conducted to evaluate the safety and tolerability of multiple daily doses of the active components of ACUROX(R) Tablets, and to determine if tolerance
to the effects of niacin develops after repeat administration. Three groups of participants received different doses of niacin combined with ...
Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity at ADA Scientific Sessions
... significant increase (>100-fold) in glucose excretion in the urine in multiple species including monkeys
Secondary improvements in glucose tolerance
and insulin sensitivity
Significant reduction in plasma glucose levels in extremely hyperglycemic animals
No harmful effects such as ...
Cardiovascular Fitness Not Affected by Cancer Treatment
... a better fitness level than they expect while some find they're not as fit as they thought. The step test gives us a better idea of their exercise tolerance
and cardiovascular fitness."
All the patients in the study were women and were diverse by age and body mass index. Their cancer diagnoses and ...
Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
... the maximum tolerated dose. The primary endpoint of the study will be safety, but patients also will be evaluated for anti-tumor activity as well as tolerance
of the drug in order to determine the optimal schedule and level of dosing. The trial has been initiated at South Texas Accelerated Research ...
Impulse Dynamics Announces Pivotal Results at the American College of Cardiology Annual Meeting Late-Breaking Session
... the results showed that, compared to the control group, patients treated with CCM signals over the other group had significantly improved exercise tolerance
as judged by an increase in peak oxygen update (p=0.02) and an improvement in quality of life as judged by a reduction in the Minnesota Living with ...
Alba Therapeutics Corporation Announces the Next Clinical Trial of Its Lead Compound, Larazotide Acetate and Promotions
... in patients with celiac disease, was a randomized, double-blind, placebo controlled, dose ranging, multicenter study to determine the safety, tolerance
and efficacy of larazotide acetate in 184 adults with controlled celiac disease during a gluten challenge. The data are promising and will be ...
Genaera Presents Preliminary Phase 1b Data for Trodusquemine (MSI-1436)
... resulting 17% differential compared to placebo subjects in the same cohort;
A 7% decrease in the area under the curve during the oral glucose tolerance
An 11.3% decrease in serum fructosamine, which is used to monitor short-term (2-3 weeks) blood sugar control; and
A 0.4% ...
Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone
... Hospital in France. "This drug is also important because it meets an unmet medical need for this group of patients. I have been impressed by the good tolerance
and efficacy of pixantrone since the first clinical trial we had with this drug in our department. We obtained excellent results in salvage therapy ...
Genaera Presents Promising Preclinical Data for Trodusquemine (MSI-1436) at Keystone Symposia
... induced dose-dependent changes in daily food intake resulting in corresponding decreases in body weight, as well as marked improvements in glucose tolerance
and lipid profile.
"The DIO rat is a standard and well-accepted preclinical model for demonstrating anti-obesity impact in this class of drugs. ...
STALLERGENES: Oralair(R) Grasses Obtains a Pediatric MA(1) in Germany
... aged between 5 and 17 years in 5 European
countries (Denmark, France, Germany, Poland, Spain), confirmed the results of
the adult trial: an excellent tolerance
profile and a statistically and
clinically significant reduction in symptoms. The pediatric and adult dosages
"This new MA(1) ...
Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2
... advanced solid tumors, Castleman's disease, or multiple myeloma. The primary endpoints of the oral dose escalating trial are determination of safety, tolerance
and PK properties of CX-4945 and to select the appropriate dose for Phase II trials. In addition, multiple mechanism-related pharmacodynamic ...
Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics
... subjects who are poorly controlled on metformin. The study will also evaluate key secondary outcomes in this population, including oral glucose tolerance
and insulin sensitivity, satiety and weight loss.
"We hope that Study 102 will help establish proof-of-concept for MSI-1436 as a highly ...
Durezol(TM) in the Treatment of Uveitis and Ganciclovir in the Treatment of Herpetic Keratitis: Studies of Treatments for Leading Causes of Blindness to Be Presented
... of ganciclovir and acyclovir for
herpetic keratitis confirms the efficacy of ganciclovir for treatment of
acute herpetic keratitis, as well as better tolerance
when compared to
acyclovir and low incidence of adverse events.
The efficacy and safety data is from an extensive clinical program
Minster Pharmaceuticals Plc Announces Positive Results from Phase II Trial of Migraine with Aura
... in schizophrenia. Worldwide rights to both compounds were
acquired from GlaxoSmithKline and the compounds benefit from comprehensive
data as a result of investment by GSK.
Tonabersat is the leading compound in an exciting new class of
selective drugs designated as neuronal gap ...
Clinical Update - Debio 9902 SR (ZT-1) for Alzheimer Patients Debiopharm Starts Tablet Formulations Bridging Study under IND
... order to minimise these cholinergic side-effects,
which is a challenge when dealing with memory deficient patients.
An AChE inhibitor with a better tolerance
profile than existing
treatments and with an easierdosing schedule could improve patient
compliance and therefore optimise the patient's treatment.
CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect
... from CEL-SCI's
Pivotal global Phase III clinical trial.
"Multikine's potential to change the tumor microenvironment and, in
doing so, break tumor tolerance
has been a long-time goal of anti-cancer
immunotherapy. We are very excited to be working with Dr. Marincola and the
NIH Clinical Center to determine ...
Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
... administered every three days over a 23 day period to
evaluate primary outcomes of safety and multiple dose PK and secondary
outcomes of oral glucose tolerance
and insulin sensitivity, satiety and
About Trodusquemine (MSI-1436)
Trodusquemine is a centrally and peripherally-acting ...
Concord Grape Juice Has No Significant Impact on Body Weight
... JA, Blumberg JB, and Mattes RD. Effects of
polyphenol-rich Concord grape juice consumption on appetite, diet, body
weight, lipid profile, glucose tolerance
and antioxidant status of humans.
Presented at The 49th Annual Meeting of the American College of Nutrition,
Arlington, Virginia, Oct 2-5, 2008.
F.D.A. Approves SANCUSO(R), the First and Only Patch for Preventing Nausea and Vomiting in Cancer Patients Undergoing Chemotherapy
... on many levels," said Barbara Rogers, CRNP, MN,
AOCN, Adult Hematology-Oncology Nurse Practitioner, Fox Chase Cancer
Center. "We should have zero tolerance
for CINV. A patch that can be
applied before treatment, releasing medication consistently into the
bloodstream over a number of days, has the ...
What is the Optimal Method of Ischemia Evaluation in WomeN: Preliminary Data from the WOMEN Study
... the ability to exercise as determined by the Duke Activity
Status (DASI) questionnaire. Women were randomized to either
electrocardiogram exercise tolerance
testing (ETT) alone or ETT with Tc-99m
tetrofosmin SPECT myocardial perfusion imaging. Ongoing results are
monitored by a Data Safety and Monitoring ...
New Research Shows Physical Therapy as Effective as Arthroscopic Knee Surgery
... that is, a gradual return to normal activities using exercises
that simulate the knee stresses of your normal activities.
A knee's tolerance
for stressful activities often decreases with age
and loss of conditioning. As a result, stresses that would not have caused
pain or injury to the ...
Vion Pharmaceuticals Enters Into Agreement With HOVON to Conduct a Phase III Clinical Trial of Cloretazine(R) in Combination With Frontline AML and MDS Therapy
... outcome ("event free
survival"), the complete remission rate, disease free survival (DFS), risk
of relapse and overall survival (OS), as well as the tolerance
toxicity, and pharmacokinetics of the combination.
The trial is expected to start this fall and will be conducted at
various sites in the ...
Nature Publication Reports on Key Role of Bile Acids in Glucose Metabolism and Insulin Signaling
... synthesis by the liver). These effects
have been attributed primarily to activation of FXR. Additionally, mice
that lack FXR have impaired glucose tolerance
and are insulin-resistant.
Dr. Schoonjans, Ph.D., a group leader at the Ecole Polytechnique
Federale de Lausanne commented, "Our research efforts ...
'Snapshots' of Eyes Could Serve as Early Warning of Diabetes or Diabetic Eye Disease, U-M Researchers Report
... has diabetes. "Because of the prevalence of
diabetes in our population, individuals with abnormally high FA would be
prompted to undergo glucose tolerance
testing," says Elner. "If the
findings were negative for diabetes, we would look for other causes of
ocular tissue dysfunction."
Both Elner and ...
Emisphere Announces Data From Independent Clinical Study of Effects of Oral GLP-1 on Glucose and Insulin Concentrations
... male subjects, was
designed to explore the pharmacodynamic effects of a single oral dose of
GLP-1 administered 15 minutes prior to an oral glucose tolerance
For the study, GLP-1 was formulated as a tablet with Emisphere's
delivery agent known as SNAC. This was Prof. Beglinger's second ...
Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss
... weight loss was also noted of
-6.1 pounds (EXE 5 mcg) and -6.8 pounds (EXE 10 mcg) compared with -3.2
pounds for placebo. In an oral glucose tolerance
test conducted in a subset
of patients (N=104), two hour serum glucose excursion decreased for EXE 5
mcg (-18.4+/-14 mg/dL) and EXE 10 mcg ...
International Diabetes Federation Grant Supports Lifestyle Intervention Study to Prevent Type 2 Diabetes in India
... have diabetes and by 2025, this number will
rocket to 69.9 million. In addition, 35 million Indians are at risk for
diabetes -impaired glucose tolerance
(IGT). India is not alone in facing
the diabetes epidemic. Over 250 million people worldwide live with diabetes
and by 2025, over 380 million people ...
Senetek PLC Announces Positive Results from Pyratine-6(TM) Clinical Trial in Patients with Acne Rosacea
... count, severity of erythema
and telangiectasia, and overall clinical improvement. Patient assessments
of signs and symptoms of rosacea and skin tolerance
were also rated at each
follow-up. In addition, transepidermal water loss measurements and facial
photography were conducted at each visit.
Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
... transcriptase inhibitor (NNRTI) or a
ritonavir-boosted PI.(6) While these combinations have been demonstrated to
be highly effective, long-term tolerance
may be limited by the toxicity
specifically associated with nucleosides, which can include neuropathy,
myopathy, renal toxicity, hepatic steatosis, ...
People With Diabetes May Have All-Natural Citrus Supplement To Help Lower Blood Glucose and Cholesterol Levels
... results suggest that when administered to people with type 2
diabetes over a longer treatment period, Diabetinol(TM) significantly
improves glucose tolerance
or the blood glucose numbers following a meal.
"Additionally, the Diabetinol(TM)-treated group showed improvements in
LDL-cholesterol levels. An ...
Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
... awakening, often
referred to as the "hangover effect." Other potential problems associated
with the GABAergic drugs include the risk of developing tolerance
dependency in at-risk populations. In addition, GABAergic drugs are
scheduled controlled substances by the Drug Enforcement Administration ...